Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Shares Down 2.8% - Time to Sell?

Key Points

• Swedish Orphan Biovitrum's stock price fell 2.8%, trading at $28.97 with a significant increase in trading volume of 1,645% compared to its average.
• The company reported an EPS of $0.24 for the last quarter, exceeding analysts' estimates and achieving a revenue of $649.61 million.
• With a market capitalization of $10.31 billion, Swedish Orphan Biovitrum operates in the biotechnology sector, specializing in treatments for haematology, immunology, and specialty care.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) shares traded down 2.8% on Tuesday . The company traded as low as $28.94 and last traded at $28.97. 500 shares changed hands during mid-day trading, an increase of 1,645% from the average session volume of 29 shares. The stock had previously closed at $29.79.

Swedish Orphan Biovitrum Price Performance

The stock has a 50 day moving average of $29.75 and a two-hundred day moving average of $29.54. The stock has a market cap of $10.31 billion, a PE ratio of 24.34 and a beta of 0.46. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.66 and a current ratio of 1.00.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.06. Swedish Orphan Biovitrum had a return on equity of 11.67% and a net margin of 16.05%. The firm had revenue of $649.61 million for the quarter, compared to analysts' expectations of $644.68 million.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.